Literature DB >> 7601425

Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells.

P J Winwood1, D Schuppan, J P Iredale, C A Kawser, A J Docherty, M J Arthur.   

Abstract

Release of 92-kd type IV collagenase/gelatinase, also known as gelatinase B, by inflammatory and tumor cells is increasingly recognized and is believed to facilitate cellular migration across basement membranes. It has been implicated in the pathogenesis of many diseases, but little is known of its cellular origin(s) and function in liver. In this study we have demonstrated synthesis and release of gelatinase B by human and rat Kupffer cells in primary culture. Northern analysis of RNA extracted from Kupffer cells stimulated with phorbol ester demonstrated a 2.8 kb transcript for gelatinase B. Immunoblotting and zymography of serum-free Kupffer cell-conditioned media demonstrated extracellular release of immunoreactive enzyme and gelatinase activity, Mr 92,000 (95,000 from rat cells). The organomercurial 4-aminophenyl mercuric acetate (APMA) activated the enzyme in vitro, indicating secretion primarily as a proenzyme. Stimulation of Kupffer cells by phorbol ester markedly induced gelatinase B release, which was inhibited by cycloheximide. In contrast, cycloheximide had no effect on constitutive secretion in culture, suggesting that there is some intracellular storage. Kupffer cell-derived gelatinase B was also partially purified and characterized. After separation by gelatin sepharose and gel filtration chromatogrpahy, gelatin-degrading activities of 95, 88, 75, and 65 kd were detected, the three lower-molecular-weight species probably representing activated forms. Enzyme activity was inhibited by ethyl-enediaminetetra-acetic acid (EDTA), but not by serine- and thiol-protease inhibitors, and was restored by zinc. Activity was also inhibited by tissue inhibitor of metalloproteinase-1 (TIMP-1) and alpha-2 macroglobulin. The partially purified enzyme rapidly degraded denatured collagens (gelatin) as well as native types III, IV, and V collagens, but had no activity against casein, types I and VI collagens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601425

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

1.  Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis.

Authors:  H Herbst; T Wege; S Milani; G Pellegrini; H D Orzechowski; W O Bechstein; P Neuhaus; A M Gressner; D Schuppan
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies.

Authors:  Jing-Ting Li; Zhang-Xiu Liao; Jie Ping; Dan Xu; Hui Wang
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

3.  Cannabinoid receptor type I modulates alcohol-induced liver fibrosis.

Authors:  Eleonora Patsenker; Matthias Stoll; Gunda Millonig; Abbas Agaimy; Till Wissniowski; Vreni Schneider; Sebastian Mueller; Rudolf Brenneisen; Helmut K Seitz; Matthias Ocker; Felix Stickel
Journal:  Mol Med       Date:  2011-08-19       Impact factor: 6.354

4.  Discoidin domain receptor 1: isoform expression and potential functions in cirrhotic human liver.

Authors:  Sunmi Song; Nicholas A Shackel; Xin M Wang; Katerina Ajami; Geoffrey W McCaughan; Mark D Gorrell
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis.

Authors:  Yury Popov; Deanna Y Sverdlov; K Ramakrishnan Bhaskar; Anisha K Sharma; Gunda Millonig; Eleonora Patsenker; Stephan Krahenbuhl; Lukas Krahenbuhl; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-01-07       Impact factor: 4.052

Review 6.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

7.  Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.

Authors:  Vincent E de Meijer; Deanna Y Sverdlov; Yury Popov; Hau D Le; Jonathan A Meisel; Vânia Nosé; Detlef Schuppan; Mark Puder
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

8.  Association of age-dependent liver injury and fibrosis with immune cell populations.

Authors:  Bradley H Collins; Zoie E Holzknecht; Kellie A Lynn; Gregory D Sempowski; Catherine C Smith; Songling Liu; William Parker; Don C Rockey
Journal:  Liver Int       Date:  2013-05-26       Impact factor: 5.828

9.  Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis.

Authors:  A E Kossakowska; D R Edwards; S S Lee; L S Urbanski; A L Stabbler; C L Zhang; B W Phillips; Y Zhang; S J Urbanski
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Amelioration of hepatic fibrosis via Padma Hepaten is associated with altered natural killer T lymphocytes.

Authors:  I Ginsburg; E Koren; A Horani; M Mahamid; S Doron; N Muhanna; J Amer; R Safadi
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.